Enzalutamide is an androgen receptor inhibitor, belonging to the class of antiandrogen drugs and hormone/antitumor drugs.
Enzalutamide may lower the seizure threshold. In clinical trials, the incidence of seizures was approximately 0.5%. Patients with a prior history of seizures or other seizure triggers (such as brain metastases, stroke, traumatic brain injury, intracranial infection, alcohol abuse, etc.) are at higher risk.
Such patients should use enzalutamide with caution. Before treatment, the physician must comprehensively assess the benefits and risks, and inform the patient and family members about the recognition and emergency management of seizures.
During treatment, concomitant use of drugs that may lower the seizure threshold (such as certain antipsychotics, antidepressants, anesthetics, etc.) should be avoided, and alcohol consumption and excessive fatigue should be avoided.
If a seizure occurs during treatment, the drug should be suspended and medical attention should be sought immediately, and the physician should evaluate whether permanent discontinuation is required.
Patients with a history of seizures must not initiate enzalutamide on their own and must use it under close monitoring by a specialist.
Enzalutamide is mainly metabolized by the liver. In patients with severe hepatic impairment (Child-Pugh C), drug exposure is significantly increased, and use is currently not recommended.
Baseline liver function should be tested before treatment, and indicators such as transaminases and bilirubin should be monitored regularly during treatment.
Patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment generally require no dose adjustment, but close monitoring is still needed.
If significant liver function abnormalities or symptoms of liver injury occur (such as jaundice, fatigue, nausea, right upper abdominal discomfort), medical attention should be sought promptly for evaluation, and drug suspension, dose reduction, or discontinuation should be considered when necessary.
Enzalutamide is contraindicated in patients with severe hepatic impairment.
Enzalutamide is contraindicated in patients allergic to enzalutamide or its excipients.
Male patients of reproductive age should use effective contraception during treatment and for a certain period after discontinuation.
Pregnant women should not come into contact with damaged or intact enzalutamide capsules.
Patients with severe cardiovascular disease or poorly controlled hypertension require careful evaluation.
Disclaimer:《People contraindicated for enzalutamide: Patients with a history of epilepsy and severe liver injury should be aware of this》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication!
Full Name:Enzalutamide、Xtandi、MDV 3100、恩杂鲁胺、恩扎卢胺、安可坦
Reference Price:$1350.00
Prescribing Information: 恩杂鲁胺是一种雄激素受体抑制剂,属于抗雄激素类药物和激素/抗肿瘤药物类别。 一、药品名称 恩杂鲁胺(Xtandi,Enzalutamide)。 二、适应症 用于治疗既往接受过多西他赛治疗的转移性去势耐受性前列腺癌患者。 三、规格 规格为40mg胶囊。 ...